within Pharmacolibrary.Drugs.ATC.C;

model C02LE01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 4.3333333333333334e-05,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.115,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006166666666666667,
    Tlag           = 600,            
    Vdp             = 0.065,
    k12             = 3.5,
    k21             = 3.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C02LE01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Combination drug containing prazosin, an alpha-1 adrenergic receptor antagonist used primarily in the management of hypertension, and diuretics, which promote diuresis for blood pressure control. Approved for use in hypertension and sometimes in heart failure. ATC code C02LE01 refers to this specific combination.</p><h4>Pharmacokinetics</h4><p>No specific published pharmacokinetic models found for the prazosin and diuretics combination as C02LE01. Parameters estimated based on prazosin alone in healthy adult volunteers for oral administration.</p><h4>References</h4><ol><li><p>Taylor, SH (1989). Clinical pharmacotherapeutics of doxazosin. <i>The American journal of medicine</i> 87(2A) 2S–11S. DOI:<a href=\"https://doi.org/10.1016/0002-9343(89)90107-1\">10.1016/0002-9343(89)90107-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2569822/\">https://pubmed.ncbi.nlm.nih.gov/2569822</a></p></li><li><p>Babamoto, KS, &amp; Hirokawa, WT (1992). Doxazosin: a new alpha 1-adrenergic antagonist. <i>Clinical pharmacy</i> 11(5) 415–427. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1349855/\">https://pubmed.ncbi.nlm.nih.gov/1349855</a></p></li><li><p>McTavish, D, &amp; Sorkin, EM (1989). Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. <i>Drugs</i> 38(1) 19–76. DOI:<a href=\"https://doi.org/10.2165/00003495-198938010-00003\">10.2165/00003495-198938010-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2670511/\">https://pubmed.ncbi.nlm.nih.gov/2670511</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C02LE01;
